Clinical Trials Logo

Clinical Trial Summary

This study will try to determine what causes learning, behavioral and emotional problems in children with chronic granulomatous disease (GCD) and other phagocyte disorders. (Phagocytes are a type of white blood cell.) Children with these disorders have frequent severe infections that require hospitalization, sometimes for long periods of time. Many of them also have problems with school, learning, behavior, anxiety and depression. This study will explore whether these latter problems are a direct result of the illness itself or are a consequence of frequent, long hospitalizations, or are due to other factors. Test findings in these children will be compared with those of children with cystic fibrosis-another disease that causes frequent infections requiring prolonged hospitalization.

Patients age 2 or older with GCD or other phagocytic disorders or cystic fibrosis may be eligible for this study. Participants (or a parent or guardian) will complete questionnaires including personal information such as age, gender and marital status, a family medical history, and information on their illness. Patients will be given various psychological and intelligence tests, and they and their parents or guardians will be interviewed by a child psychiatrist. The tests and interviews take a total of about 5 hours and are given in two or three separate sessions.

The tests may reveal problems such as learning disorders, attention-deficit hyperactivity disorder, anxiety, or depression. If any of these problems are identified, appropriate referrals will be made for specialized services, such as special school placement, tutoring, or counseling.


Clinical Trial Description

Leukocyte disorders are predominantly genetic diseases in which phagocytes fail to function normally resulting in recurrent infections. Children with these disorders are subject to recurrent, severe, often life-threatening infections and are hospitalized more frequently than their peers. Frequent hospitalization and chronic illness can affect growth, development, socialization, and educational opportunities.

Specifically, chronic granulomatous disease (CGD) is an inherited disorder in which phagocytes fail to generate an oxidative burst. In 26 patients followed at the NIH tested for behavioral problems at the request of a parent or staff member, we have observed a 23% rate of mild mental retardation. However, it is not clear whether this is due to CGD per se or the recurrent infections and hospitalizations. We seek to determine the prevalence of cognitive disabilities in children with CGD and other leukocyte disorders. We seek to determine whether abnormal leukocyte functioning may be related to specific behavioral phenotypes or impaired cognitive functioning. We also seek to clarify whether impaired cognitive functioning is related to the effects of frequent and prolonged hospitalization or other variables such as severity of illness in this population. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00005933
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date June 2000
Completion date July 2005

See also
  Status Clinical Trial Phase
Withdrawn NCT03278912 - Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT04136028 - IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease Early Phase 1
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Terminated NCT03080480 - Pioglitazone Therapy for Chronic Granulomatous Disease Phase 1/Phase 2
Terminated NCT00394316 - Gene Therapy for Chronic Granulomatous Disease Early Phase 1
Recruiting NCT03910452 - Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide Early Phase 1
Terminated NCT02282904 - Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide Phase 1/Phase 2
Terminated NCT02926963 - Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease. N/A
Completed NCT00006417 - Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease Phase 2
Completed NCT00368446 - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT06162936 - Neutrophil Oxidative Burst in Early and Late Onset Pediatric Inflammatory Bowel Disease
Enrolling by invitation NCT06253507 - pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD) Phase 1/Phase 2
Terminated NCT05915897 - Whole Blood Biospecimen Collection for Subjects With Chronic Granulomatous Disease (CGD)
Terminated NCT00325078 - Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease Phase 1/Phase 2
Completed NCT00001317 - A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of Childhood Phase 4
Completed NCT03548818 - Role of Interferon-gamma 1-b (IFN-γ) on Cells of the Innate Immune System: Functional, Biochemical and Gene Expression Studies in Patients With Chronic Granulomatous Disease
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00578643 - Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease Phase 2